HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays
- 10 September 2010
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (14) , 2171-2179
Abstract
Background: Because of high intersubtype HIV-1 genetic variability, it has been shown that subtype-specific patterns of resistance to antiretroviral drugs exist. We wished to ascertain whether this might be true for integrase inhibitors. Methods: We compared the susceptibility of subtype B and C HIV-1 integrase enzymes, harboring the previously reported resistance mutations E92Q, N155H, and E92Q/N155H, to clinically relevant integrase inhibitors. This was performed biochemically using a microtiter plate system. Results: Subtype C integrase enzymes bearing the resistance mutations E92Q/N155H were approximately 10-fold more susceptible to each of two integrase inhibitors, raltegravir and elvitegravir, than were subtype B recombinant integrase containing the same mutations. Conclusion: Polymorphic differences within the subtype B and C integrase genes likely cause variations in the contribution of N155H alone or in combination with E92Q to drug resistance. It is possible that different viral subtypes may favor different mutational pathways, potentially leading to varying levels of drug resistance among different subtypes.Keywords
This publication has 39 references indexed in Scilit:
- Retroviral intasome assembly and inhibition of DNA strand transferNature, 2010
- Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In VivoAntimicrobial Agents and Chemotherapy, 2010
- Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic PathwaysJournal of Virology, 2009
- Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase InhibitorsAntimicrobial Agents and Chemotherapy, 2009
- Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 IntegraseAntimicrobial Agents and Chemotherapy, 2009
- Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 IntegraseJournal of Virology, 2008
- Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase MutantsBiochemistry, 2008
- Biochemical Analysis of HIV-1 Integrase Variants Resistant to Strand Transfer InhibitorsJournal of Biological Chemistry, 2008
- Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In VitroAntimicrobial Agents and Chemotherapy, 2008
- Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)Journal of Virology, 2008